Fujirebio and Sysmex Are Expanding Their Cdmo Partnership Into the Field of Neurodegenerative Diseases in Connection With Their Immunoassay Collaboration

Friday, December 01, 2023

Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their contract development partnership. and contract development and manufacturing organization (CDMO) for Sysmex's HISCL™ series automated immunoassay system in the field of neurodegenerative diseases. This was preceded by discussions based on the framework agreement signed in October 2023* on business cooperation in the field of immunoassays.

While Fujirebio has been developing special reagents for the Sysmex HISCL™ series since 2020, the two companies agreed to intensify their partnership in October 2023. Both companies believe that the combination of their respective competencies and strengths in immunoassays will accelerate their global expansion and contribute to the development and advancement of immunoassays. Since then, both companies have discussed ways to strengthen their collaboration.

Under the new agreement, Fujirebio will develop reagents in the field of neurodegenerative diseases such as Alzheimer's disease that can be used in the Sysmex HISCL™ series for cerebrospinal fluid (CSF)-based tests and blood-based tests. This will accelerate the expansion of Sysmex's testing parameters in these diseases and further expand Sysmex's global footprint in immunoassays.

Fujirebio and Sysmex will continue to work together to develop the tests and bring them into use as early as possible.

* Press release “Fujirebio and Sysmex enter into framework agreement for commercial cooperation in the field of immunoassays” dated October 10, 2023

About Fujirebio

Fujirebio, a member of HU Group Holdings Inc., is a global R&D-driven company that continuously develops new in vitro diagnostic testing technologies and unique biomarkers with high clinical value. Our company has set itself the goal of creating new values ​​in healthcare and thereby making a contribution to human health and the future of medical care.

Our global teams in Japan, Asia, Europe and the USA are focused on delivering products with the highest quality standards to our customers and partners. We value partnerships with other industry leaders who share their knowledge, skills and key materials to deliver, develop or manufacture diagnostic solutions for a variety of platforms.

For more information about Fujirebio, visit www.fujirebio.com .

About Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its founding in 1968, Sysmex has focused on diagnostics as its core business and today supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics and co-create unique value in the areas of personalized medicine and novel treatments in line with its long-term vision “Together for a better healthcare journey”. To achieve this vision, Sysmex identifies and reviews sustainable development goals (SDGs) and materiality (priority themes) to ensure its growth as a company that creates both social and economic value. Through its unique technology, solutions and collaboration with various partners, Sysmex creates new values ​​and fulfills people's general desire for a longer and healthier life. For more information about Sysmex, visit www.sysmex.co.jp/en/ .

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.

Contacts
For media representatives:
Public Relations Section, Public Relations/Sustainability Department,
HU Group Holdings, Inc.
Tel.: +81-3-6279-0884
Email: pr@hugp.com

For investors and analysts:
IR/SR Dept.
Tel: +81-3-5909-3337
Email: ir@hugp.com

Source: businesswire.com